ARIPIPRAZOLE | A203908 | AUROBINDO PHARMA LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
OTSUKA PHARMACEUTICAL CO., LTD. v. AUROBINDO PHARMA LIMITED et al 3 patentsANDA 203908Aripiprazole | D.N.J. | 2014-05-23 | Terminated 2018-02-07 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.1711
per ea
Lowest NADAC/Unit
$0.0980
per ea
Brand NDCs
0
Generic NDCs
12
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 65862066505ARIPIPRAZOLE 20 MG TABLET | $0.1711 | EA | Generic | — | 2026-06-17 |
| 65862066530ARIPIPRAZOLE 20 MG TABLET | $0.1711 | EA | Generic | — | 2026-06-17 |
| 65862066630ARIPIPRAZOLE 30 MG TABLET | $0.1670 | EA | Generic | — | 2026-06-17 |
| 65862066605ARIPIPRAZOLE 30 MG TABLET | $0.1670 | EA | Generic | — | 2026-06-17 |
| 65862066405ARIPIPRAZOLE 15 MG TABLET | $0.1289 | EA | Generic | — | 2026-06-17 |
| 65862066430ARIPIPRAZOLE 15 MG TABLET | $0.1289 | EA | Generic | — | 2026-06-17 |
Showing 6 of 12 NDCs.
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.